You’ve already learned that sufficient protein intake (above 0.5g/lb of body weight) can assist with adequate IGF-1 and growth hormone production. Whey protein provides your body with a complete profile of necessary amino acids, including leucine. Leucine is an amino acid that promotes greater muscle protein synthesis and assists the body while gaining lean muscle mass and losing fat tissue simultaneously.
Obesity affects as many as one in five adults in developed countries. Metabolic estimates that the potential worldwide market for effective obesity drugs is as much as $20 billion, far more than the current market of $1.5 billion. This is partly due to the potential need for chronically obese people to take obesity drugs such as AOD9604 and also because patients are put off using currently available drugs because of their marginal efficacy or side-effects.
One of the important reasons we consume protein is that it helps to keep our bodies full. While many people use protein powders for this purpose, a lot of protein powders are filled with fillers or unnatural additives. Collagen protein, on the other hand, is a clean protein - in its pure form, it has no additives or sweeteners - that can help keep you full and promote satiety. Several studies have focused on the benefits of consuming collagen in helping people who are trying to lose weight. In a study assessing hunger hormones in 10 obese patients and 12 patients of normal weight, researchers found that the intake of gelatin (a substance derived from collagen itself) actually increased the satiety hormone, which means the subjects were more likely to adhere to their weight loss diets(1). If you could maintain satiety longer, you may be on the road to effective weight loss simply by reducing your own hunger.
Figure 5A demonstrates that chronic administration of AOD9604 or hGH has no significant effect on the weight of white adipose tissue in either WT orβ 3-KO mice. However, in brown adipose tissue, both AOD9604 and hGH significantly reduced the size of the brown adipose tissue mass in the WT mice (Fig. 5B), by 20% and 31% (P < 0.05), respectively, as was found previously in the C57BL/6J ob/ob mice (Fig. 2B). Importantly, this effect was not observed in β3-KO mice.
An Australian-owned obesity drug, developed by Melbourne-based biotechnology company Metabolic Pharmaceuticals Limited, is set to enter final human trials next year after successfully completing a Phase 2b human trial which proved that the drug induces weight loss and is very well tolerated with no evidence of the side effects commonly experienced with existing obesity drugs.
There is evidence of involvement of organised crime in supply of the substances. The substances are offered for sale via the internet. Many of the substances are promoted as safe alternatives to traditional performance enhancing substances such as the anabolic steroids. Suppliers are making unproven assertions about the efficacy and safety of the substances.
SARMs are selective androgen receptor modulators. Androgens are naturally occurring hormones—such as testosterone—that regulate the development and maintenance of male sex characteristics. SARMs provide the benefits of anabolic steroids (i.e., increased muscle mass/strength, fat loss, increased bone density, increased libido) without the quantity and/or severity of unwanted effects. SARMs are not toxic to the liver, separating them from most oral steroids and making them an attractive treatment option to those looking to benefit from anabolic steroid drugs.
Finally, the hexadecapeptide AOD9604 did not induce allergenic reactions when consumed over 24 weeks. Blood of patients was analyzed for the presence of anti-AOD9604 antibody formation at various times and at the end of the studies (latest time point after 24 weeks). In none of the performed studies, at no time, were anti-AOD9604 antibodies detected in serum collected from any subjects in any treatment group.
The PCR reaction mixture contained 1 U Taq polymerase (Life Technologies, Inc.), the supplied buffer [20 mM Tris-HCl (pH 8.4) and 50 mM KCl], 200 μM dNTPs, 2 mM Mg-acetate, 2.5 pmol of forward primer, 2.5 pmol labeled reverse primer, and cDNA in a vol of 10 μl. The PCR reactions were carried out in a Hybaid PCR Sprint machine (Hybaid, Ltd., Middlesex, UK). Following the initial heating of the samples at 95 C for 2 min, each cycle of amplification consisted of 30 sec at 95 C, 30 sec at 64 C, and 30 sec at 72 C. It was found that 24 cycles were optimum for the amplification process.
Results: After a single injection of CJC 1295, there were dose dependent increases in mean plasma GH concentrations by 2- to 10-fold for 6 d or more and in mean plasma IGF-I concentrations by 1.5- to 3-fold for 9–11 d. The estimated half-life of CJC 1295 was 5.8–8.1 d. After multiple CJC 1295 doses, mean IGF-I levels remained above baseline for up to 28 d. No serious adverse reactions were reported.
Whilst not illegal to buy AOD9604 in Australia, AOD9604 does not have approval by the TGA, which means it is not allowed to be sold on the basis of it having any pharmaceutical or performance enhancing benefits. It has not been approved by any pharmaceutical authority worldwide, except for the previously mentioned "Generally Regarded As Safe" designation by the FDA. AOD9604 is currently classed by the World Anti Doping Agency (WADA) as a non-approved substance, which means it is not legal for use by athletes in competition. WADA policy is to ban all substances that are suspected of being performance-enhancing, even in the absence of clinical proof (1,2).
Phenylephrine is a direct alpha-1 adrenergic agonist, with weak alpha-2 adrenergic agonist activity. It also has very weak beta-adrenergic effects, but at therapeutic doses there are no significant stimulating beta-1 adrenergic effects on the heart, or on the bronchial airways, or on peripheral blood vessels. This contrasts with pseudoephedrine, which has greater beta-adrenergic activity. The effect on the alpha-adrenergic receptors leads to local vasoconstriction and shrinking of mucous membranes. There is no anti-histamine effect. The drug is readily and completely absorbed following oral administration, undergoing extensive first pass metabolism in the intestinal wall and in the liver leading to some variability in individual pharmacokinetics. Nasal decongestion is apparent within 15 to 20 minutes and persists for up to 4 hours (AHFS 2007).
The acute effect of AOD9604 and BRL37344 (aβ 3-AR agonist) on energy expenditure and substrate oxidation rates in WT and KO mice was also assessed. KO animals had lower energy expenditure, lower fat oxidation, and increased glucose oxidation, compared with the WT controls (data not shown). Injection of WT mice with a single dose of BRL37344 or AOD9604 increased energy expenditure and fat oxidation and decreased glucose oxidation. In the KO animals, BRL37344 failed to elicit any response in these metabolic parameters, clearly demonstrating that its effects are mediated exclusively through the β3-AR. AOD9604 did elicit a response in the KO mice, increasing fat oxidation and energy expenditure, although the response was not as great as in WT mice, suggesting that β3-ARs are not responsible for the acute biological response of AOD9604 on lipid metabolism. This is consistent with our previous findings in which AOD9604 was shown not to bind to the β3-AR (11). The size and duration of the metabolic responses to AOD9604 in the β3-AR KO animals was different from that observed in the control wild-type mice. The response was more rapid, shorter in duration, and greater in peak response. This may be because the KO animals are more acutely sensitive to lipolytic agents, a compensation for the ablation of the major lipolytic receptor.
To buy our premium peptides online you will need to complete a simple online medical questionnaire. This is a legal requirement due to the regulation of Peptides in Australia. We cannot legally advertise specific Peptides to the general public without first ascertaining you are over 18 years of age and have submitted the required medical questionnaire. Learn more about Muscle Peptides Australia services.